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Abstract
Background: Cancer stem cells (CSCs) have been invoked in resistance, recurrence and metastasis of cancer.
Consequently, curative cancer treatments may be contingent on CSC selective approaches. Of particular interest
in this respect is the ionophore salinomycin, a natural product shown to be 100-fold more active against CSCs
than clinically used paclitaxel. We have previously reported that synthetic salinomycin derivatives display increased activity
against breast cancer cell lines. Herein we specifically investigate the CSC selectivity of the most active member in each
class of C20-O-acylated analogs as well as a C1-methyl ester analog incapable of charge-neutral metal ion transport.
Methods: JIMT-1 breast cancer cells were treated with three C20-O-acylated analogs, the C1-methyl ester of salinomycin,
and salinomycin. The effects of treatment on the CSC-related CD44+/CD24− and the aldehyde dehydrogenase positive
(ALDH+) populations were determined using flow cytometry. The survival ability of CSCs after treatment was investigated
with a colony formation assay under serum free conditions. The effect of the compounds on cell migration was evaluated
using wound-healing and Boyden chamber assays. The expression of vimentin, related to mesenchymal traits
and expression of E-cadherin and β-catenin, related to the epithelial traits, were investigated using immunofluorescence
microscopy.
Results: Treatment with each of the three C20-acylated analogs efficiently decreased the putative CSC population as
reflected by reduction of the CD44+/CD24− and ALDH+ populations already at a 50 nM concentration. In addition, colony
forming efficiency and cell migration were reduced, and the expression of the epithelial markers E-cadherin and β-catenin
at the cell surface were increased. In contrast, salinomycin used at the same concentration did not significantly influence
the CSC population and the C1-methyl ester was inactive even at a 20 μM concentration.
Conclusions: Synthetic structural analogs of salinomycin, previously shown to exhibit increased activity against cancer
cells, also exhibited improved activity against CSCs across several assays even at nanomolar concentrations where
salinomycin was found inactive. The methyl ester analog of salinomycin, incapable of charge-neutral metal ion
transport, did not show activity in CSC assays, lending experimental support to ionophoric stress as the molecular
initiating event for the CSC effects of salinomycin and related structures.
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Breast cancer is the leading cause of cancer death among
women worldwide. Often, this outcome is a consequence
of recurrence following years of disease-free life after a
completed initial treatment [1]. Recurrence has been
linked to certain treatment resistant cancer cells,
coined cancer stem cells (CSCs), which share many of
the properties associated with regular stem cells includ-
ing self-renewal and differentiation [2]. Several studies
have shown enrichment of CSCs following conventional
chemotherapeutic treatment, both in vivo and in cancer
cell lines [3, 4]. This has lead to the proposal that the
chemotherapeutic drugs mainly target bulk cancer cells
while sparing cells with CSC properties [5, 6]. Curative
treatments may therefore be contingent on therapies that
target both CSCs and bulk cancer cells, presumably by a
combination of conventional therapies and CSC selective
drugs. Of particular interest in a breast cancer context is
the natural product salinomycin. Salinomycin was identi-
fied in a screen for breast CSC inhibition [7] and has sub-
sequently been shown to inhibit CSCs of many cancer
types [8–10]. Salinomycin has been shown to inhibit cell
migration and cell proliferation as well as inducing apop-
tosis and autophagy [11–15]. Proposed mechanisms in-
clude inhibition of Wnt [16–18] and Hedgehog signaling
[19], inhibition of multidrug efflux systems [20, 21], induc-
tion of reactive oxygen species [22, 23], cleavage of poly-
ADP-ribose polymerase [24, 25], and induction of DNA
damage [26]. However, the actual molecular initiating
event in the CSC or cancer cell adverse outcome pathways
has not been clarified. As evidenced by the number of dif-
ferent mechanisms proposed, the actual initiating event
may be obfuscated by the high treatment concentrations
often used. It is well known that salinomycin is a potent
ionophore with the capacity to transport alkali metal ions
and it has been suggested that it acts in biological mem-
branes by promoting potassium ion efflux [27, 28].
Despite the mechanistic uncertainty, salinomycin has
been used in limited clinical trials showing positive re-
sponses [28, 29]. Towards increasing the clinical rele-
vance of salinomycin, there is thus considerable interestFig. 1 Chemical structures of salinomycin (SA) and synthetic salinomycin a
in blue. IC50 in JIMT-1 cells given as mean ± SEM [30]in more active and selective structures acting through
the same mechanism as well as developing an under-
standing of how such compounds selectively reduce
CSC populations. We have previously demonstrated that
selective chemical modification of salinomycin at the
C20 hydroxyl group can be used to access significantly
more active analog structures with IC50 values down to
below one fifth of that of the native structure in two
breast cancer cell lines [30]. In fact, these compounds
represent the most active salinomycins known. In
addition, chemical modifications at other positions of
salinomycin as well as the anti proliferative effects of
such derivatives have been described [30–35].
Herein, we show that the enhanced activity of the most
active analog in each of the ester, carbamate and carbon-
ate series of C20-O-acylated structures identified in our
previous study (Fig. 1) also translates to superior selectiv-
ity against putative CSCs as compared to salinomycin it-
self. Treatment with each of the C20-acylated analogs
efficiently reduced traits related to CSC activity in three
different assays already at low nanomolar concentrations
where salinomycin itself did not show activity. The unique
potency of C20-O-acylated structures should be of interest
in clinical settings where specific pharmacological activity
at low concentrations is highly favorable. Of mechanistic
significance, salinomycin C1-methyl ester (Fig. 1), a struc-
ture lacking the primary ion-binding motif of salinomycin,
the carboxylic acid moiety, was also evaluated in parallel.
Despite sharing the basic molecular framework of salino-
mycin, this structure, which is incapable of charge-
neutral metal ion transport, did not show CSC selective
properties. This finding is in line with disturbances in
ion gradients as the main molecular initiating event
and suggests that CSCs can, at least in part, be inhib-
ited by such a mechanism.Methods
In this study, the well-established commercially available
human breast cancer cell line JIMT-1 (ACC589) was
used and no ethical approval was required.nalogs. Structural differences compared to salinomycin are highlighted
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The human breast carcinoma cell line JIMT-1 (ACC589)
was purchased from the German Collection of Microor-
ganisms and Cell Cultures (DSMZ) and was routinely
cultured in Dulbecco’s modified Eagle’s medium/Ham’s
F-12 nutrient mixture (1/1) supplemented with 10 %
fetal calf serum (FCS), nonessential amino acids (1 mM),
insulin (10 μg/ml), penicillin (100 U/ml) and strepto-
mycin (100 μg/ml). The JIMT-1 cell line was established
from a pleural metastasis of a 62-year old patient with
breast cancer who was clinically resistant to trastuzumab
[36]. It is a well-characterized estrogen receptor negative
and HER2 amplified cell line belonging to the HER2 plus
sub-type of breast cancer [36, 37]. The JIMT-1 cell line
contains phenotypically different cell populations based
on expression of CSC markers CD44, CD24 and ALDH
[38]. This cell line has been used in several studies to in-
vestigate effects on the CSC subpopulation [39–42].
The JIMT-1 cell cultures were kept at 37 °C in a hu-
midified incubator with 5 % CO2 in air. If not specified
below, the cells were seeded at a density of 20,000 cells/
cm2 using 0.2 - 0.3 ml of medium per cm2 in a tissue
culture dish with appropriate size for the respective as-
says. Active compounds were added 24 h after seeding,
and the cells were sampled for the various analyses after
72 h of treatment. Cell counting was performed in a
hemocytometer.
Compounds
Technical grade salinomycin (12 %) was obtained from
Chemtronica AB. This material was purified as described
previously [30] and salinomycin was isolated and used as
its sodium salt. Salinomycin analogs 2a-c and methyl
ester 3 were synthesized according to [30]. Analogs 2a-c
were used as the respective sodium salt. The compounds
were diluted in 100 % dimethyl sulfoxide (DMSO) to a
10 mM stock solution which was kept at 4 °C. The com-
pounds were diluted in phosphate-buffered saline (PBS)
to give working solutions at appropriate concentrations.
The controls were supplemented with PBS containing
DMSO at the same concentrations as in the working so-
lutions of the compounds. The final DMSO concentra-
tion was 0.2 % when using the C20-O-acylated analogs
at the IC50 concentration [30]. An IC50 was not obtained
for the salinomycin C1-methyl ester [30] and it was used
at a 20 μM concentration in experiments comparing ef-
fects at IC50. The DMSO concentration was 0.0005 %
when using the compounds at a 50 nM concentration.
Cell cycle analysis by flow cytometry
After 72 h of treatment, cells were harvested by trypsini-
zation and fixed in ice-cold 70 % ethanol for at least 1 h
at −20 °C. The cells were then stained and analyzed as
described previously [43]. The assay does not distinguishbetween G0 and G1 cells, thus, when G1 is mentioned in
the text and figures it denotes both populations. Since
the method removes the cell membranes, cells in mitosis
(M) are not included in the assay.
Western blot
After 72 h of treatment, cells were harvested using Accu-
tase (Sigma) for 10 min at 37 °C, then counted, pelleted
and stored at −80 °C until further use. The Western blot
was performed as described previously [42].
Cell surface markers identified by flow cytometry
Cells were harvested using Accutase and identified based
on their expression of the cell surface markers CD44
and CD24 using a BD Accuri C6 as described previously
[35]. Antibodies used for flow cytometry (CD44-fluores-
cein isothiocyanate (FITC)-conjugated (clone G44-26),
CD24-phycoerythrin (PE)-conjugated (clone ML5) and
PE-conjugated or FITC-conjugated mouse IgG1 isotype
controls (MOPC-21)) were purchased from BD Biosci-
ences. Labeling with 7-aminoactinomycin D (7AAD) was
initially used to gate only live cells, but this staining
could be omitted since dead cells were typically not
seen and usage of 7AAD should be minimized as this is
a potent carcinogen. In addition, the cell harvesting
procedure included a rinsing step that removed de-
tached dead cells.
ALDEFLUOR assay
The ALDEFLUOR kit (Stem Cell Technologies) was
used according to the manufacturer’s protocol. The cells
were harvested using Accutase and after cell counting,
two test tubes containing 200,000 cells in assay buffer
were prepared for each sample. One of the test tubes
was used as negative control receiving the specific
ALDH inhibitor diethylaminobenzaldehyde (DEAB).
Then the ALDH substrate BODIPY-amino acetaldehyde
was added to both tubes which were incubated for
45 min at 37 °C. After incubation, the cells were pelleted
by centrifugation and the cells were resuspended in
500 μl assay buffer before analysis in a BD Accuri C6
flow cytometer. DEAB-treated cells served as control to
set the ALDH+ region for each sample. The CFlow soft-
ware was used to evaluate the data.
Colony formation assay in soft agar
The colony formation assay was performed as described
previously [35].
Wound-healing assay
JIMT-1 cells were seeded in 6-well plates (125,000 cells/
cm2) and allowed to attach for 24 h resulting in a con-
fluent layer of cells. The medium was removed and three
scratches (wound areas) were made in the cell layer with
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PBS, medium without FCS containing 0.0005 % DMSO
(control) or the respective compound at a concentration
of 50 nM was added to the wells. The scratch area was
photographed directly (time 0), as well as after 24, 48
and 72 h of treatment in an inverted phase contrast
microscope. The migration was estimated by measuring
the scratch area at 0, 24, 48 and 72 h of treatment with
ImageJ 1.47v software. The scratch area at each time
point was divided with the area at 0 h to obtain a meas-
ure of wound closure. The wound area was defined as
0 % closed at 0 h for each sample.
Boyden chamber cell migration assay
JIMT-1 cells were detached with Accutase, the cell num-
ber determined by counting in a hemocytometer and the
cells were then diluted in serum free medium to a con-
centration of 50,000 cells/250 μl. The cell suspension
was incubated for 30 min at 37 °C in a water bath to
acclimatize the cells to the serum free medium. The cells
in serum-free medium were then seeded (50,000 cells) in
tissue culture inserts with membranes having 8.0 μm
pores (BD FalconTM Cell Culture Inserts). The inserts
were then placed into the wells of 24-well plates con-
taining 500 μl medium with 10 % FCS. The compounds
were added to both the inserts and to the wells to a con-
centration of 50 nM while control received 0.0005 %
DMSO. The 24-well plates were incubated in the CO2
incubator for 24 h. The cells that had migrated through
the pores of the membrane were fixed and stained with
cell stain (Millipore, part No. 90144) for 20 min. The
trans wells were rinsed in Millipore water and non-
migrated cells removed with cotton swabs. The mem-
branes were then left to air-dry. Ten photos were taken
of each membrane in an inverted phase contrast micro-
scope. Migrated cells were counted and the mean of mi-
grated cells for each sample was compared to control.
Immunofluorescence microscopy
JIMT-1 cells were plated on poly-L-lysine-coated glass
slides and treated with 50 nM compound or 0.0005 %
DMSO as control for 72 h. After fixation in 3.7 % parafor-
maldehyde (in PBS) for 15 min and subsequent washing
in PBS, the cells were permeabilized with PBS containing
1 % Tween 20 and 1 % bovine serum albumin in a single
step. The cells were incubated with primary antibody
against vimentin (1:100), β-catenin (1:500) or E-cadherin
(1:100) for 1 h at room temperature. Antibodies against
vimentin (ab8978) and E-cadherin (ab1416) were pur-
chased from Abcam. Antibody against β-catenin (610154)
was purchased from BD Biosciences. After washing, the
cells were incubated for 1 h with the Alexa Fluor 488 goat
anti mouse (1:300) antibody (Invitrogen). Slides were
counter-stained with bisbenzimide (Hoechst 33258) (1 μg/ml in PBS) for 2 min and finally washed with PBS before
mounting. The cells were viewed in an Olympus/Nikon
epifluorescence microscope (Olympus Optical Co. Ltd.)
and photos were taken with a digital camera (Nikon
Imaging Japan Inc.). Each slide was photographed at
randomly chosen areas (at least 8 areas).
Statistical analysis
The software program GraphPad Prism 6 was used for
statistical analysis. A one-way ANOVA test, using the no
matching or paring option, was used to detect difference
between control and treated samples. To compare the
mean of each column with the mean of a control, the
Dunnet multiple comparisons test was applied using a
95 % confidence interval.
Results
C20-O-acylated analogs are more efficient than salinomycin
against breast CSCs at a 50 nM concentration
Breast CSCs have been identified based on a high ex-
pression of CD44 paired with absent/low expression of
CD24 on the cell surface [44]. We have previously
shown that salinomycin (1) gave the highest selective ac-
tivity against CD44+/CD24− cells at ~ IC25 in the breast
cancer cell line JIMT-1 [35]. Thus, we decided to investi-
gate the CSC activity of the analogs 2a-c in this cell line
using a 50 nM concentration, which corresponds to the
approximate IC25 values for these structures. At this
concentration, we found that treatment with each of the
C20 analogs efficiently reduced the CD44+/CD24− sub-
population while treatment with salinomycin or the sali-
nomycin C1-methyl ester 3 had no observable effect
(Fig. 2a and Additional file 1: Figure S1). We have previ-
ously shown that treatment with varying concentrations
of salinomycin gives a U-shaped dose response curve
with the maximum reduction of the CD44+/CD24−
around IC25 [35], and this was also found to be the case
for the more active analogs as exemplified by carbamate
2a (Additional file 2: Figure S2). To account for this ef-
fect in JIMT-1 cells following treatment with salinomy-
cin or either of the two related structures SY-1 and
18,19-dihydro SY-1, we have previously discussed the re-
lation between a decrease in the total cell number and
the decrease in the population of CD44+/CD24− cells at
various concentrations [35]. At concentrations up to
IC25, the reduction in cell number only originated from
a selective reduction of CD44+/CD24− cells but at con-
centrations above IC25, all populations were affected and
at higher concentrations there was little or no reduction
in the CD44+/CD24− population resulting in a U-shape
dose response curve [35].
The most common trait of CSCs of different tumor ori-
gins appears to be expression of aldehyde dehydrogenase
(ALDH) [45]. Treatment with 50 nM of C20 analogs
Fig. 2 The analogs 2a–c are more efficient than salinomycin against CSCs at a 50 nM concentration. a The CD44+/CD24− population evaluated
using flow cytometry after 72 h of treatment. b The ALDH+ population evaluated using flow cytometry after 72 h of treatment. c Colony forming
efficiency evaluated using a serum free soft agar assay. The cells were treated for 72 h and then reseeded at cloning density. The colonies were
counted after 2 weeks of incubation. d Colonies obtained from the serum free soft agar assay. Bars = 40 μm. Data are represented as mean ± SEM for
n = 4. *P< 0.05, **P < 0.01, ***P < 0.001. ns: no significant difference. SA: salinomycin, 2a: carbamate, 2b: acetate, 2c: carbonate and 3: C1-methyl ester
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with salinomycin or the salinomycin C1-methyl ester had
no observable effect (Fig. 2b and Additional file 3: Figure
S3). In contrast to the U-shaped dose response curve for
CD44+/CD24−, varying the concentrations of salinomycin
gave a dose dependent reduction in ALDH+ cells
(Additional file 4: Figure S4).
Colony forming efficiency in serum free soft agar is
a functional assay which has been used to investigate
survival potential of cells with stem cell properties in
cancer cell lines [46]. We found that treatment with
analogs at a 50 nM concentration reduced the colony
forming efficiency and colony size of JIMT-1 cells
while treatment with salinomycin or the C1-methyl
ester again had no observable effect at the same con-
centration (Fig. 2c and d).
Treatment with C20 analogs increase the expression of
epithelial markers and decrease the expression of vimentin
CSCs have been shown to exhibit properties that arise in
the epithelial to mesenchymal transition (EMT) process
and these properties contribute to the metastasis of cancer[47–49]. Compounds that reduce the mesenchymal prop-
erties of CSCs should be of interest as a strategy for pre-
venting metastasis. Some important traits of EMT are the
loss of E-cadherin and β-catenin on the cell surface. β-
Catenin is localized at cell-cell junctions and its associ-
ation with E-cadherin leads to a stable epithelial structure.
A loss of β-catenin from the cell membrane borders is
seen in migratory mesenchymal cells [50, 51]. An add-
itional marker for cell mobility is an increased expression
of the mesenchymal cytoskeletal protein vimentin.
Treatment with C20 analogs for 72 h increased the E-
cadherin and β-catenin expression levels at the cell
membrane while treatment with salinomycin and the
C1-methyl ester did not give a noticeable effect on these
protein levels (Fig. 3a and b). The expression of vimentin
was decreased both by treatment with the C20 analogs
and by salinomycin (Fig. 3c).
Taken together, the results show that the C20 ana-
logs were more efficient at a 50 nM concentration
than salinomycin in increasing the expression of the
epithelial markers at the cell surface. All compounds
tested except the C1-methyl ester also decreased the
Fig. 3 Treatment with the analogs 2a–c induce expression of E-cadherin and β-catenin at the cell surface. The cells were treated with a 50 nM
concentration of the compounds for 72 h. a–c E-cadherin, β-catenin and vimentin, respectively, detected with immunofluorescence microscopy
after appropriate labeling with specific primary antibodies followed by secondary Alexa Fluor 488-conjugated antibodies (green). Nuclei were
stained with bisbenzimide (blue). Bars = 20 μm. SA: salinomycin, 2a: carbamate, 2b: acetate, 2c: carbonate and 3: C1-methyl ester
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this concentration.
Treatment with C20-O-acylated analogs reduce cell
migration
A decreased expression of vimentin and increased expres-
sion of E-cadherin and β-catenin at the cell surface should
lead to a cellular functional effect manifested in decreased
migration. We thus investigated the effect of both the C20
analogs and salinomycin on cell migration using a 50 nM
concentration in wound-healing and Boyden chamber as-
says. Both assays showed that the acylated analogs as well
as salinomycin reduced cell migration (Fig. 4). However,
each of the acylated analogs was more efficient in inhibit-
ing wound closure and cell migration than salinomycin at
this concentration. The C1-methyl ester had no effect on
migration compared to control.
Salinomycin and the C20 analogs exert CSC and cell cycle
effects through the same mechanism of action
Compounds that exert activity through the same molecu-
lar mechanism should give similar effects upon treatment
at IC50. When treating cells with each of the analogs and
salinomycin at the respective IC50 (Fig. 1), all compoundsFig. 4 Cell migration after treatment with a 50 nM concentration of salinom
b Representative images of wound healing at 72 h after scratching. c Quan
after 24 h of treatment. d Representative images of migrated cells. JIMT-1 c
pores in medium containing the indicated compound. After 24 h of treatm
stained and photographed. The arrow points to a migrated cell. The small
in (b) and (d) = 200 μm. SA: salinomycin, 2a: carbamate, 2b: acetate, 2c: caexcept the C1-methyl ester (used at a 20 μM concentra-
tion) reduced the CD44+/CD24− population to a similar
extent. Moreover, treatment at IC50 also decreased the
ALDH+ cell population to around 50 % of control while
the C1-methyl ester at a 20 μM concentration was in-
active in this assay (Fig. 5a and b, Additional files 5
and 6: Figure S5 and S6). The same trend translated
also to colony formation, although the C1-methyl ester
at 20 μM gave a slight decrease in colony forming effi-
ciency (Fig. 5c and d). The C1-methyl ester is a xeno-
biotic and is used at a high concentration compared to
the other compounds and thus some toxicity is not
surprising. When compared to control, treatment with
all compounds including the C1-methyl ester resulted
in a significant decrease in the number of colonies
formed (p < 0.0001 for SA, 2a and 2b; p = 0.0002 for
2c; p = 0.007 for 3).
We also investigated the effects on cell cycle phase dis-
tribution and induction of cell death. When the cells were
treated at the IC50 of salinomycin or the C20 analogs, the
G1 phase increased and the S phase decreased (Fig. 5e). In
contrast, cultures treated with the C1-methyl ester showed
the same cell cycle phase distribution as control (Fig. 5e).
None of the compounds induced cell death as evidencedycin or salinomycin analogs 2a-c. a Quantification of wound healing.
tification of migrated cells in a Boyden chamber cell migration assay
ells were plated in trans wells with membranes containing 8.0 μm
ent, cells that had migrated to the bottom of the trans well were
dots are the pores. Data are represented as mean ± SEM for n = 5. Bars
rbonate and 3: C1-methyl ester. **P < 0.01 compared to control
Fig. 5 Treatment with IC50 of salinomycin and the analogs 2a-c result in similar effects on CSCs and cell proliferation. a The CD44
+/CD24− population
evaluated by flow cytometry after 72 h of treatment. b The ALDH+ population evaluated by flow cytometry after 72 h of treatment. c Colony forming
efficiency evaluated using a serum free soft agar assay. The cells were treated for 72 h and then reseeded at cloning density. The colonies were counted
after 2 weeks of incubation. d Colonies obtained from the serum free soft agar assay. Bars = 40 μm. e Cell cycle phase distribution evaluated by flow
cytometry. f Representative Western blots used for densitometric scanning. g–h Expression of cyclin A2 and p27, respectively. Data are represented as
mean ± SEM for n≥ 3. The columns in (a–d) show mean ± SEM for n= 4. *P < 0.05, **P< 0.01, ***P< 0.001. ns: no significant difference. SA: salinomycin,
2a: carbamate, 2b: acetate, 2c: carbonate and 3: C1-methyl ester
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(not shown). To gain insight into the molecular cause of
the increase in the G1 phase, proteins that have major
roles in cell cycle progression through the G1 and S phases
were investigated by Western blot analysis. The levels of
cyclins D1 and E1, important for G1 progression and G1/S
transition, respectively, did not change compared to con-
trol after treatment with any of the compounds (not
shown). However, the level of cyclin A2, important for S
phase progression, was significantly reduced by all com-
pounds (Fig. 5f and g). The decrease in cyclin A2 is thus a
reflection of a decreased S phase. The G1 accumulation in
cells treated with IC50 of salinomycin or the C20 acylated
analogs can be attributed to the significantly increased ex-
pression of the CDK/cyclin inhibitor p27 (Fig. 5f and h).
The p27 level was not affected in cells treated with the
C1-methyl ester. Expression of the CDK/cyclin inhibitor
p21 was not affected by treatment with any of the com-
pounds (not shown).
The cell cycle investigation shows that treatment with a
50 nM concentration of the compounds resulted in a
slight increase in the G1 phase of 2c-treated cells com-
pared to control while treatment with the other com-
pounds resulted in a similar cell cycle phase distribution
as control (Additional file 7: Figure S7). The level of cyclin
A2 was the same in all treatment groups while p27 was in-
creased in cells treated with 2b and 2c but substantially
less compared to treatment with IC50 concentrations
(compare Fig. 5 with Additional file 7: Figure S7). Analysis
of the sub-G1 peak of DNA histograms did not show any
sub-G1 peak as evidence of cell death in any of the treat-
ment groups at a 50 nM concentration (not shown).
Discussion
Using several independent CSC assays, a series of syn-
thetic C20-O-acylated analogs of salinomycin reduced
the putative CSC population in the JIMT-1 breast cancer
cell line already at a 50 nM concentration where salino-
mycin itself does not show activity. The synthetic ana-
logs are thus significantly more active against CSCs than
the native structure. The mechanism of action appears
to be the same for all these compounds as several inde-
pendent assays show that salinomycin and the C20 ana-
logs give similar responses at the respective IC50.
Although salinomycin has been investigated exten-
sively in a CSC context in recent years, the exact mech-
anism of action of this compound is not well
understood. To this end, it is important that the C1-
methyl ester analog of salinomycin, a compound that re-
tains the molecular structure of salinomycin, but dis-
plays an over three orders of magnitude reduced ion-
binding ability [31] and is essentially incapable of
charge-neutral ion transport, does not influence
CSC-related properties even when used at higherconcentrations. This gives experimental credence to the
molecular initiating event for salinomycin and its C20
analogs as being related to disturbed membrane
dependent ion gradients. These changes presumably
then influence various signal transduction pathways and
cell functions, which subsequently result in a decrease in
the number of CSCs as well the mesenchymal traits of
the cell population. Our data thus emphasize a signifi-
cant role of the antiporter capacity of salinomycin and
its more active C20 analogs rather than interaction with
a specific cellular target. This notion is further corrobo-
rated by the prior observations that the related iono-
phores monensin and nigericin have similar effects as
salinomycin [7, 52]. The nature of the properties re-
quired for the high activity against CSCs of such struc-
tures however remains an open question. In particular, a
potential connection between the CSC response and the
alkali ion binding selectivity and transport efficiency is
of interest in this context.
In addition to self-renewal and differentiation, CSCs
have been shown to possess increased metastatic cap-
acity, which is related to the process of EMT [53]. Sali-
nomycin treatment has previously been shown to inhibit
the ability of several cancer cell lines including prostate,
colorectal and human bone marrow-derived mesenchy-
mal stem cells to migrate when used at concentrations
ranging from 50 nM to 10 μM [9, 11, 14, 22, 54, 55].
Our results show that the C20 analogs inhibited cell mi-
gration even more efficiently than salinomycin at a 50
nM concentration. Additionally, the expression of the
epithelial markers E-cadherin and β-catenin at the cell
surface was increased and the expression of the mesen-
chymal marker vimentin was decreased after treatment
with the C20 analogs 2a-c. In contrast, treatment with
50 nM salinomycin did not affect the expression of E-
cadherin and β-catenin at the cell surface. The vimentin
levels decreased after salinomycin treatment, which may
explain the decreased rate of migration shown in the
wound-healing and Boyden chamber assays although
this effect was less pronounced than for the C20 analogs.
Our data thus show that treatment with a 50 nM con-
centration of the analogs 2a-c increased the number of
cells with epithelial phenotype while cells with mesen-
chymal phenotype decreased. In principle, the origin of
this effect may be an induction of mesenchymal to epi-
thelial transition (MET) i.e. a change in phenotype, but
the same outcome would be achieved if there were se-
lective death or growth inhibition of mesenchymal cells.
An investigation of the sub-G1 region in the cell cycle
phase distribution of DNA histograms did not show in-
duction of cell death upon treatment with a 50 nM con-
centration of the analogs. As cell proliferation is slightly
inhibited at IC25, the results can be interpreted as origin-
ating from inhibition of proliferation of mesenchymal
Huang et al. BMC Cancer  (2016) 16:145 Page 10 of 12cells and induction of MET in these cells. Similar results
have been obtained when treating JIMT-1 cells with the
anticancer polyamine analog PG11047 [42].
More active salinomycin analogs are of interest in
light of the recent case reports where salinomycin
treatment resulted in partial tumor and metastasis re-
gression of breast cancer [28, 29]. Our results show
that the synthetic C20 analogs exhibited improved
activity against breast CSCs compared to salinomycin
using several well-accepted traits of CSCs. These
compounds moreover efficiently induced MET result-
ing in a decreased capacity of cell migration, a prop-
erty closely related with metastasis of cancer.
Importantly, these effects were seen for the synthetic
C20 analogs already at low nanomolar concentrations
where salinomycin itself was inactive. In particular,
acetate 2b and the hydrolytically more stable ethyl
carbonate 2c are attractive for further investigations
as these compounds display similar enhanced activ-
ities in both MTT and CSC assays and can moreover
be readily synthesized in high yields from abundantly
available salinomycin [30].Conclusions
We have previously shown that salinomycin derivatives,
readily available in just a few synthetic steps, are signifi-
cantly more active than salinomycin against breast cancer
cells. Herein we show that these improvements in activity
also translate to an enhanced selectivity against CSCs
already at low nanomolar concentrations where salinomy-
cin itself is inactive as shown by complementary marker-
based and functional cell assays. Additionally, we show
that traits associated with mesenchymal cells including
cell migration and vimentin expression are efficiently re-
duced by the analog structures at low concentrations,
while epithelial traits such as E-cadherin and β-catenin ex-
pression at the cell surface are increased reflecting a mes-
enchymal to epithelial transition. The similar responses
across the assays when treating cells at the respective IC50
strengthens that salinomycin and its C20-acylated analogs,
although varying in potency, exert their influence on the
CSC population through a shared mechanism. While a
number of downstream effects have been invoked in
explaining the activity of salinomycin against CSCs, the
molecular initiating event has remained unclear. Using the
synthetic structural analogs as mechanistic probes, we
lend experimental credence to ionophoric stress as the
origin of the observed inhibition of CSCs. We anticipate
that structural analogs of salinomycin that elicit similar
cellular responses compared to the native structure but at
significantly lower concentrations will be of immediate
value both towards clinical relevance and for further
mechanistic and biological investigations.Additional files
Additional file 1: Figure S1. Representative cytograms of cell surface
markers CD44 and CD24 obtained using flow cytometry. JIMT-1 cells were
treated with 50 nM salinomycin or salinomycin analogs for 72 h. SA:
salinomycin, 2a: carbamate, 2b: acetate, 2c: carbonate and 3: C1-methyl
ester. (DOCX 1340 kb)
Additional file 2: Figure S2. U-shaped dose response curve found for
the CD44+ /CD24− population in N–ethyl carbamate 2a-treated JIMT-1
cells. JIMT-1 cells were treated with 2a for 72 h at the indicated concentrations.
The effect on the CD44+/CD24− population was determined using flow
cytometry. Data are represented as mean ± SEM for n= 4. (DOCX 41 kb)
Additional file 3: Figure S3. Representative cytograms of ALDH assay
obtained using flow cytometry. JIMT-1 cells were treated with 50 nM
salinomycin or salinomycin analogs for 72 h. SA: salinomycin, 2a: carbamate,
2b: acetate, 2c: carbonate and 3: C1-methyl ester. (DOCX 1678 kb)
Additional file 4: Figure S4. Salinomycin treatment decreases the
proportion of ALDH+ in a dose dependent manner. JIMT-1 cells were
treated with salinomycin for 72 h at the indicated concentrations. The
effect on the ALDH+ population was determined using flow cytometry.
Data are represented as mean ± SEM for n = 3. (DOCX 38 kb)
Additional file 5: Figure S5. Representative cytograms of cell surface
markers CD44 and CD24 obtained using flow cytometry. JIMT-1 cells were
treated with salinomycin or salinomycin analogs at IC50 for 72 h. SA:
salinomycin, 2a: carbamate, 2b: acetate, 2c: carbonate and 3: C1-methyl
ester. (DOCX 1331 kb)
Additional file 6: Figure S6. Representative cytograms of ALDH assay
obtained using flow cytometry. JIMT-1 cells were treated with salinomycin
or salinomycin analogs at IC50 for 72 h. SA: salinomycin, 2a: carbamate, 2b:
acetate, 2c: carbonate and 3: C1-methyl ester. (DOCX 1597 kb)
Additional file 7: Figure S7. Cell cycle effects of treating with 50 nM
salinomycin or the analogs 2a-c for 72 h. (a) Cell cycle phase distribution
evaluated using flow cytometry. (b) Representative Western blots used for
densitometric scanning to obtain the data in (c) and (d). (c-d) Expression of
cyclin A2 and p27, respectively. The columns in (c) and (d) show mean ±
SEM for n = 6. * P < 0.05. SA: salinomycin, 2a: carbamate, 2b: acetate, 2c:
carbonate and 3: C1-methyl ester. (JPG 737 kb)
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